PDCD1LG2, also known as PD-L2, has been previously elevated in Epstein-Barr virus (EBV)-positive tumors (Cancer Genome Atlas Research Network, 2014), but its expression in BLCA is unclear, and in our study, PDCD1LG2 expression was found to be decreased in early-stage patients and essentially flat in advanced patients compared with normal adjacent tissues. The gene discussed is PDCD1LG2; the disease is bladder transitional cell carcinoma.